Capricor Therapeutics Nears Key Milestones After Earnings Call

Capricor Therapeutics, Inc. ((CAPR)) has held its Q4 earnings call. Read on for the main highlights of the call.

Capricor Therapeutics’ latest earnings call struck an overall optimistic tone, underscored by major regulatory progress and strong Phase 3 data for deramycin in Duchenne muscular dystrophy. Management balanced this with a candid discussion of rising expenses, zero current revenue and remaining regulatory and manufacturing uncertainties that investors will need to monitor closely.

BLA Acceptance and PDUFA Date

The FDA’s acceptance of Capricor’s Class II BLA resubmission for deramycin marks a pivotal regulatory milestone for the company. With a PDUFA target action date set for August 22, 2026, investors now have a clear timeline for a potential first commercial approval in Duchenne cardiomyopathy.

Robust HOPE-3 Phase 3 Efficacy Signal

The Phase 3 HOPE‑3 trial in 106 patients met its primary endpoint on Performance of the Upper Limb and all Type 1 error‑controlled secondary endpoints, strengthening confidence in deramycin’s clinical profile. Notably, left ventricular ejection fraction decline was slowed by 91% in evaluable patients and reached stronger statistical significance in the cardiomyopathy subgroup.

Functional and Imaging Benefits Reinforce the Story

Capricor highlighted statistically significant gains in a home‑based Duchenne Video Assessment, which aligned with the PUL results and adds real‑world context to the efficacy data. MRI late gadolinium enhancement also showed a meaningful reduction in cardiac fibrosis versus placebo, providing structural evidence that supports the functional improvements.

Safety Profile and Long-Term Exposure

Management emphasized deramycin’s safety, drawing on more than 800 intravenous infusions delivered across studies. Open‑label extension data, with some patients on continuous therapy for up to five years and over 100 patients treated in extension studies, further underpins the drug’s long‑term tolerability.

Manufacturing and Commercial Readiness

The company’s in‑house GMP facility in San Diego has successfully completed FDA pre‑license inspection, with all observations addressed, positioning Capricor for potential launch. Current capacity is designed for about 250 patients per year, with an expansion to add around six clean rooms and ultimately support roughly 2,500 patients annually by late 2027.

Balance Sheet Strength and Capital Raise

Capricor has bolstered its balance sheet with late‑2025 financings, including a public offering and use of its ATM facility, giving the company more flexibility ahead of potential commercialization. Management signaled confidence that current capital should fund operations into 2027, though the exact cash figure needs clarification given numerical inconsistencies in the call.

Strategic and Visibility Wins

The company secured an uplisting to the NASDAQ Global Select Market, a move that can enhance liquidity and institutional visibility for the stock. Management also highlighted the potential eligibility for a transferable priority review voucher tied to deramycin approval and plans to submit the full HOPE‑3 data set for peer‑reviewed publication.

Exosome Platform and StealthX Progress

Beyond deramycin, Capricor advanced its exosome‑based StealthX platform, noting that the Phase 1 COVID vaccine study was well tolerated, even if neutralization results were modest. Learnings from this program are feeding into next‑generation engineered exosomes aimed at muscle targeting and multi‑payload delivery, with IND‑enabling work targeting a filing around 2027.

Revenue Drop Highlights Precommercial Status

Financially, the company reported no revenue in 2025 versus $22.3 million in 2024, reflecting the wind‑down of prior milestone and upfront payments. This underscores that Capricor remains a development‑stage biotech fully dependent on external capital until deramycin, or another asset, reaches the market.

Rising Operating Costs and Wider Losses

Operating expenses climbed to about $108.1 million in 2025 from $64.8 million in 2024 as Capricor invested heavily in clinical, regulatory and manufacturing infrastructure. As a result, net loss widened sharply to roughly $105.0 million from $40.5 million, a reminder that the path to commercialization is capital intensive.

Regulatory and Labeling Uncertainties

Despite the accepted BLA, key questions remain around the final label, including whether approval will focus narrowly on cardiomyopathy or span a broader Duchenne population. Potential age or functional status restrictions are also unresolved, leaving some uncertainty around the ultimate commercial opportunity and payer positioning.

Early StealthX Immunogenicity Limitations

The StealthX COVID program delivered encouraging safety outcomes but only limited neutralization at tested doses, tempering near‑term enthusiasm for this specific asset. NIAID has asked the company to evaluate higher doses and possible adjuvants, extending timelines and adding another layer of development risk to the platform.

Near-Term Manufacturing Capacity Constraints

While the existing facility can cover early commercial needs and clinical demand, its roughly 250‑patient annual capacity may constrain uptake if deramycin is approved and demand ramps quickly. The planned expansion to support around 2,500 patients per year will not be fully online until late 2027, creating a potential temporary bottleneck.

Ambiguity Around Cash and PRV Upside

Management and the CFO referenced different cash figures, creating some ambiguity around the exact year‑end balance, although both imply a multi‑year runway. The potential future value of a priority review voucher also remains uncertain, as market prices have fluctuated and timelines for any sale are not yet defined.

Forward-Looking Guidance and Outlook

Looking ahead, Capricor’s main catalyst is the August 22, 2026 PDUFA date for deramycin, supported by the HOPE‑3 dataset and extensive safety exposure. Management expects existing cash to fund operations into 2027, anticipates manufacturing expansion to come online in late 2027 and is positioning the exosome platform for an IND‑stage transition around that time frame as well.

Capricor’s earnings call painted a picture of a company approaching an inflection point, with deramycin’s BLA under FDA review and pivotal data in hand. For investors, the key watchpoints will be labeling negotiations, execution on manufacturing expansion and the company’s ability to manage cash burn as it navigates the final stretch toward potential commercialization.